Loading organizations...
Keros Therapeutics is a technology company.
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders. The company’s core technical approach centers on understanding and modulating the transforming growth factor-beta (TGF-β) family of proteins. These proteins are master regulators of cell and tissue development, including red blood cell and platelet production, as well as the growth, repair, and maintenance of various tissues such as blood vessels, heart tissue, bone, skeletal muscle, and adipose tissue.
The company was founded in December 2015, with Jasbir S. Seehra, Ph.D., serving as its President and Chief Executive Officer since 2016. Dr. Seehra, a biopharmaceutical veteran and co-founder of Acceleron Pharma, brought significant expertise in TGF-β biology to Keros. This experience informed the foundational insight that manipulating the TGF-β signaling pathways could unlock therapeutic benefits for a broad range of diseases with high unmet medical needs.
Keros Therapeutics aims to deliver significant clinical benefit to patients afflicted with disorders stemming from dysfunctional TGF-β signaling. Its vision involves developing differentiated product candidates designed to alter these pathways, providing disease-modifying treatments. The company's long-term goal is to leverage its deep scientific expertise in TGF-β biology to fuel ongoing research and bring additional innovative therapeutic options to individuals with complex medical conditions.
Keros Therapeutics has raised $90.0M across 3 funding rounds.
Keros Therapeutics has raised $90.0M in total across 3 funding rounds.
Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for hematologic and musculoskeletal disorders with high unmet medical needs.[1] It focuses on leveraging the transforming growth factor-Beta (TGF-β) family of proteins, which regulate red blood cell and platelet production, as well as muscle and bone growth, repair, and maintenance.[1]
The company serves patients suffering from conditions like myelodysplastic syndromes (MDS), myelofibrosis, anemia from iron imbalance, fibrodysplasia ossificans progressiva (FOP), osteoporosis, osteogenesis imperfecta, and pulmonary arterial hypertension.[1] Its lead candidates—KER-050 (for cytopenias in MDS and myelofibrosis), KER-047 (for iron imbalance anemia and FOP), and KER-012 (for bone loss disorders and pulmonary arterial hypertension)—address critical gaps in therapies for blood cell deficiencies and bone/muscle pathologies.[1] As a clinical-stage player, Keros demonstrates growth momentum through advancing multiple product candidates in development and commercialization pipelines.[1]
Keros Therapeutics emerged as a leader in TGF-β pathway modulation for hematologic and musculoskeletal disorders, though specific founding details like year or founders are not detailed in available sources.[1] The company's idea stems from deep expertise in the TGF-β family, recognized as master regulators of hematopoiesis (red blood cell and platelet production) and musculoskeletal health, targeting diseases with significant unmet needs.[1] Early traction likely built on this scientific foundation, positioning Keros as a clinical-stage biopharma advancing protein and small molecule therapeutics from discovery to potential commercialization.[1]
Keros rides the wave of precision medicine in biopharma, particularly in TGF-β signaling modulation, amid rising demand for therapies targeting hematologic malignancies and rare musculoskeletal diseases.[1] Timing aligns with advances in understanding cytokine pathways like TGF-β, which drive innovation in anemia, cytopenias, and bone disorders where traditional treatments fall short.[1] Market forces favoring Keros include aging populations increasing osteoporosis and MDS prevalence, plus growing investment in orphan drugs for myelofibrosis and FOP.[1] It influences the ecosystem by pioneering TGF-β-based interventions, potentially setting standards for next-gen biotherapeutics in underserved areas.[1]
Keros is poised to advance its pipeline toward key clinical milestones, with KER-050 potentially nearing later-stage trials for MDS-related cytopenias and KER-012 expanding into pulmonary hypertension.[1] Trends like biologics innovation and rare disease focus will shape its path, bolstered by TGF-β expertise amid biopharma's shift to pathway-specific therapies.[1] Its influence may grow through partnerships or approvals, solidifying leadership in hematologic and musculoskeletal innovation—echoing its core mission to deliver novel treatments for patients with high unmet needs.[1]
Keros Therapeutics has raised $90.0M in total across 3 funding rounds.
Keros Therapeutics's investors include Flare Capital Partners, Foresite Capital, IPD Capital, Pontifax Venture Capital, Arkin Bio Ventures, Global Health Sciences Fund, Medison Pharma, Partners Innovation Fund.
Keros Therapeutics has raised $90.0M across 3 funding rounds. Most recently, it raised $56.0M Series C in March 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2020 | $56.0M Series C | Flare Capital Partners, Foresite Capital, IPD Capital, Pontifax Venture Capital | |
| Jan 1, 2019 | $23.0M Series B | Pontifax Venture Capital, Arkin Bio Ventures, Global Health Sciences Fund, Medison Pharma, Partners Innovation Fund | |
| Nov 1, 2017 | $11.0M Series A | Pontifax Venture Capital |